$ECOC

ABVC BIOPHARMA, INC.

CIK:0001173313|SEC Filings

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenues
Cost of revenues
Gross loss
Operating expenses
Selling, general and administrative expenses	503,778	690,094	1,255,776	1,305,465
Research and development expenses	22,707	33,276	55,807	62,137
Stock-based compensation	253,041	1,571,613	1,040,415	1,620,386
Total operating expenses	779,526	2,294,983	2,351,998	2,987,988
Loss from operations	(779,526)	(2,294,983)	(2,351,998)	(2,987,988)
Other income (expense)
Interest income	683	19,139	4,448	38,210
Interest expense	(42,323)	(129,413)	(91,700)	(352,380)
Operating sublease income	17,207	12,000	29,207	24,000
Gain (loss) on foreign exchange	11,378	136,148	(39,778)	126,236
Loss on investment in equity securities	(24,766)	(44,917)	(56,182)	(95,794)
Other income (expenses)	6,866	(7,180)	5,585	(5,680)
Total other expenses	(30,955)	(14,223)	(148,420)	(265,408)
Loss before provision income tax	(810,481)	(2,309,206)	(2,500,418)	(3,253,396)
Provision for income tax expense		23,627		23,627
Net loss	(810,481)	(2,332,833)	(2,500,418)	(3,277,023)
Net loss attributable to noncontrolling interests	(73,547)	(75,811)	(203,242)	(177,926)
Net loss attributed to ABVC and subsidiaries	(736,934)	(2,257,022)	(2,297,176)	(3,099,097)
Foreign currency translation adjustment	(1,457)	39,640	10,591	38,147
Comprehensive loss	$ (738,391)	$ (2,217,382)	$ (2,286,585)	$ (3,060,950)
Net loss per share:
Basic (in Dollars per share)	$ (0.03)	$ (0.13)	$ (0.09)	$ (0.19)
Diluted (in Dollars per share)	$ (0.03)	$ (0.13)	$ (0.09)	$ (0.19)
Weighted average number of common shares outstanding:
Basic (in Shares)	26,058,884	17,386,536	25,755,386	16,184,064
Diluted (in Shares)	26,058,884	17,386,536	25,755,386	16,184,064

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
Net loss	$ (2,500,418)	$ (3,277,023)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	12,299	13,718
Stock-based compensation	1,040,415	1,620,386
Other non-cash expenses	(866)	317,279
Loss on investment in equity securities	56,182	95,794
Loss on short-term investment	1,204
Amortization of right-of-use asset	169,352	181,062
Changes in operating assets and liabilities:
Inventories		(11,460)
Prepaid expenses and other current assets	204,221	(73,786)
Due from related parties	(24,007)	(190,394)
Accrued expenses and other current liabilities	38,398	23,248
Tenant security deposit	31,167	24,710
Taxes payables	(11,889)	23,521
Operating lease liabilities	(154,714)	(181,062)
Net cash used in operating activities	(1,138,656)	(1,434,007)
Cash flows from investing activities
Loan to related parties	(147,572)	(808,240)
Payment for Long-term investment	(668,403)
Payment for convertible notes receivable- related party	(32,000)
Repayment from related parties	793,567	142,461
Net cash used in investing activities	(54,408)	(665,779)
Cash flows from financing activities
Repayment of short-term loans	(691,299)	(58,875)
Proceeds from exercise of warrants	102,000	411,667
Proceeds from convertible notes payable		9,010
Proceeds from private offerings	319,492	1,868,750
Proceeds from common stock subscription		170,000
Due to related parties, net	153,835	(44,469)
Net cash provided by financing activities	(115,972)	2,356,083
Effect of exchange rate changes on cash and cash equivalents and restricted cash	13,995	(43,786)
Net decrease in cash and cash equivalents and restricted cash	(1,295,041)	212,511
Cash and cash equivalents and restricted cash
Beginning	1,326,985	863,815
Ending	31,944	1,076,326
Cash paid during the year for:
Interest expense paid	4,570	10,505
Income taxes paid	(1,209)	1,969
Non-cash financing and investing activities
Acquiring control of the land		7,670,000
Issuance of common stock for conversion of debt		263,847
Conversion of convertible note due from related parties to equity investment		$ 563,819

Unaudited Condensed Consolidated Balance Sheets $ in Millions	Jun. 30, 2026 USD ($)	Dec. 31, 2025 USD ($)
Current Assets
Cash and cash equivalents	$ 31,944	$ 681,480
Restricted cash		645,505
Short-term investments	62,420	64,354
Prepaid expense and other current assets	151,559	346,616
Total Current Assets	411,729	2,501,343
Property and equipment, net	12,831,939	12,835,409
Operating lease right-of-use assets	1,743,926	1,913,278
Long-term investments	2,489,697	1,878,465
Prepayment for long-term investments	1,124,842	1,124,842
Prepayment for asset acquisition	691,900	691,900
Other non-current assets	106,682	116,966
Total Assets	19,400,715	21,062,203
Current Liabilities
Short-term bank and other loans	59,462	755,512
Accrued expenses and other current liabilities	4,200,027	4,161,629
Contract liabilities	12,600	12,600
Operating lease liabilities	358,107	317,557
Taxes payable		11,964
Total Current Liabilities	5,694,505	6,163,976
Tenant security deposit	31,167
Operating lease liability – non-current	1,405,483	1,600,747
Total Liabilities	7,131,155	7,764,723
COMMITMENTS AND CONTINGENCIES
Equity
Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 authorized, 25,767,664 and 25,053,193 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	26,220	25,053
Stock to be issued	105,000	359,000
Additional paid-in capital	97,722,998	96,008,258
Accumulated deficit	(79,155,537)	(76,858,361)
Accumulated other comprehensive income	498,193	487,602
Treasury stock	(8,909,691)	(8,909,691)
Total Stockholders’ equity	10,287,183	11,111,861
Noncontrolling interest	1,982,377	2,185,619
Total Equity	12,269,560	13,297,480
Total Liabilities and Equity	19,400,715	21,062,203
Related Party
Current Assets
Due from related parties	136,344	763,388
Convertible notes receivable – related parties	29,462
Current Liabilities
Due to related parties	265,299	105,704
Convertible notes payable – related parties	240,000	240,000
Third Parties
Current Liabilities
Convertible notes payable – third parties	$ 559,010	$ 559,010